Document Type

Journal Article

Publication Title

Molecular Brain

ISSN

1756-6606

Volume

12

Issue

1

First Page

26

Last Page

26

PubMed ID

30922367

Publisher

Springer Nature

School

Centre of Excellence for Alzheimer’s Disease Research and Care / School of Medical and Health Sciences

Comments

Originally published as: Zetterberg, H., & Burnham, S. C. (2019). Blood-based molecular biomarkers for Alzheimer’s disease. Molecular Brain, 12(1), Article 26. Original publication available here

Abstract

A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer's disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD pathology. This may be related in part to the limited capacity of the current health systems to select those people likely to have AD pathology in order to confirm the diagnosis with available cerebrospinal fluid and imaging biomarkers at memory clinics. In the current narrative review, we summarize the literature on candidate blood tests for AD that could be implemented in primary care settings and used for the effective identification of individuals at increased risk of AD pathology, who could be referred for potential inclusion in clinical trials or future approved treatments following additional testing. We give an updated account of blood-based candidate biomarkers and biomarker panels for AD-related brain changes. Our analysis centres on biomarker candidates that have been replicated in more than one study and discusses the need of further studies to achieve the goal of a primary care-based screening algorithm for AD.

DOI

10.1186/s13041-019-0448-1

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

 
COinS